Market News & Trends
Female Health Company & Aspen Park Pharmaceuticals Announce FDA Clears Pathway
The Female Health Company (FHC) and Aspen Park Pharmaceuticals, Inc. (APP) recently announced that the US FDA has agreed to an expedited regulatory pathway for…
Phillips-Medsize to be Acquired by Molex
Phillips-Medisize Corporation recently announced it has entered into a binding agreement to be acquired by Molex LLC, a global manufacturer of complete interconnect solutions. Phillips-Medisize…
Portola Pharmaceuticals Receives Complete Response Letter From FDA
Portola Pharmaceuticals Inc. recently announced it has received a Complete Response Letter (CRL) from the US FDA regarding its Biologics License Application (BLA) for AndexXa…
Piramal Enterprises Enters Agreement to acquire Ash Stevens
Piramal Enterprises Limited recently announced that its wholly owned subsidiary in the US has entered into an agreement to acquire 100% stake in Ash Stevens…
Crown Bioscience Center of Excellence Expands Services
Crown Bioscience has expanded its oncology services with new models, cell lines, and assays at its Center of Excellence for Oncology in San Diego. The…
ACG ACPL Becomes the First Empty Hard Capsule Manufacturer in Asia to Receive EXCiPACT™ Certification
Dahanu, India 19th August, 2016 ACG Worldwide is pleased to announce that ACG Associated Capsules Pvt. Ltd. (ACG ACPL) has received…
ACG ACPL Becomes the First Empty Hard Capsule Manufacturer in Asia to Receive EXCiPACT™ Certification
Dahanu, India 19th August, 2016 ACG Worldwide is pleased to announce that ACG Associated Capsules Pvt. Ltd. (ACG ACPL) has received…
Cystic Fibrosis Therapies Will Push Vertex Ahead of GSK in $46.6-Billion Respiratory Market
The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably…
Cystic Fibrosis Therapies Will Push Vertex Ahead of GSK in $46.6-Billion Respiratory Market
The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably…
Novel Lipid-Altering Therapies Will Steer ACS Market Beyond $12 Billion
The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound…
Novel Lipid-Altering Therapies Will Steer ACS Market Beyond $12 Billion
The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound…
Spark Therapeutics Announces New Positive Data From Continuation of Phase III Trial
Spark Therapeutics recently announced new data from the continuation of the Phase III trial of voretigene neparvovec (formerly referred to as SPK-RPE65), its most advanced…
Scientists Find Important Clue to Restoring Muscle Function
ChromaDex Corp. recently announced that University of Pennsylvania researchers have uncovered an important clue as to why our muscles weaken as we age, and how…
Pluristem’s Phase III Study Wins $8-Million Grant
Pluristem Therapeutics Inc. recently announced that its critical limb ischemia (CLI) program in the European Union has been awarded an $8-million grant. The grant is…
Amphivena Therapeutics Announces Acceptance of IND Application
Amphivena Therapeutics, Inc. recently announced that the US FDA has accepted an investigational new drug (IND) application for AMV564, the company’s proprietary T-cell redirecting bispecific…
Allergan Sales to Consolidate Four New Jersey Locations
The state Economic Development Authority approved Allergan's application for Grow NJ tax breaks that it said would keep 1,019 workers in the state, and add…
NIH Using PharmaJet in DNA Vaccine Clinical Trial
PharmaJet recently announced that the National Institutes of Health will use the PharmaJet Stratis needle-free device in a DNA vaccine clinical trial for the Zika…
OmniComm Systems Signs Multi-Million Dollar, 5-Year Agreement
OmniComm Systems, Inc. recently announced that one of the top five medical research universities in the US, selected OmniComm TrialMaster EDC and related services to…
Catalyst Biosciences Announces Agreement to Sell Three NNR Assets to Attenua
Catalyst Biosciences, Inc. recently announced it has entered into a definitive agreement to sell to Attenua, Inc. certain oral Neuronal Nicotinic Receptor (NNR) assets that…
Mayne Pharma Acquires Portfolio From Teva & Allergan
Mayne Pharma has recently completed its $652-million transaction with Teva and Allergan, taking ownership of 37 approved and five filed generic pharmaceutical products. This transaction…
